Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Roland Morley
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Phase Ia Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) in Patients With Recurrent Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Indoleamine 2,3-Dioxygenase 1 (IDO1)
Science-Business eXchange
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Refractory, Locally Advanced or Metastatic Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3 Dioxygenase 1
Biophysical Journal
Biophysics
O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors
Annals of Oncology
Medicine
Oncology
Hematology
Phase I Study of the Pan-Pi3k Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors
Anticancer Research
Medicine
Cancer Research
Oncology
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I Study of the mTOR Inhibitor Ridaforolimus and the HDAC Inhibitor Vorinostat in Advanced Renal Cell Carcinoma and Other Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
